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Abstract
Introduction: The aim of this study was to investigate the effects of hyperbaric oxygen therapy (HBOT) on glycaemic control, atheroscle-
rosis, inflammatory markers, and other clinical and laboratory parameters in patients undergoing systemic HBOT for diabetic foot ulcer-
ations.
Material and methods: Twenty-eight patients with Wagner grade 2–4 diabetic foot ulcerations were included. All patients were given
100% oxygen at 2.4 absolute atmosphere (ATA) for about 105 minutes, five times a week for a total of 30 sessions. Fasting blood glucose
(FBG), haemoglobin A1c (HbA1c), homeostasis model measurement-insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP),
uric acid, mean platelet volume (MPV), complete blood count, and lipid profile were tested.
Results: Upon completion of treatment, a statistically significant improvement was observed in the mean values of all assessed parame-
ters.
Conclusions: HBOT was shown to have beneficial effects on atherosclerosis and glycaemic control in diabetic patients. Further large-scale
randomized studies are needed to study the systemic effects of HBOT. (Pol J Endocrinol 2010; 61 (3): 275–279)
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Streszczenie
Wstęp: Celem badania była ocena wpływu leczenia tlenem w komorze hiperbarycznej (HBOT, hyperbaric oxygen therapy) na kontrolę
glikemii, czynniki ryzyka miażdżycy, wskaźniki zapalenia oraz inne kliniczne i laboratoryjne parametry u chorych z owrzodzeniem
w przebiegu zespołu stopy cukrzycowej poddanych systemowej HBOT.
Materiał i metody: Do badania włączono 28 chorych z owrzodzeniem stopy 2–4 stopnia według skali Wagnera. Wszyscy chorzy odbyli
30 sesji terapii 100-procentowym tlenem przy ciśnieniu 2,4 ATA przez około 105 minut, 5 razy w tygodniu. Zmierzono następujące parametry:
glikemię na czczo, odsetek HbA1c, wskaźnik insulinooporności HOMA-IR, stężenie wysokoczułego białka C-reaktywnego (hs-CRP, high
sensitivity C-reactive protein), stężenie kwasu moczowego, średnią objętość płytek krwi, a ponadto zbadano morfologię krwi i profil lipidowy.
Wyniki: Po zakończeniu terapii stwierdzono istotną poprawę średnich wartości wszystkich badanych parametrów.
Wnioski: Wykazano, że HBOT wpływa korzystnie na czynniki ryzyka miażdżycy i kontrolę glikemii u chorych na cukrzycę. Potrzebne są
dalsze, prowadzone na szeroką skalę badania z randomizacją, aby ocenić ogólnoustrojowe efekty HBOT.
(Endokrynol Pol 2010; 61 (3): 275–279)
Słowa kluczowe: leczenie tlenem hiperbarycznym, cukrzyca, stopa cukrzycowa, miażdżyca, kontrola glikemii
Introduction
Atherosclerotic complications represent the most sig-
nificant cause of morbidity and mortality in diabetic
patients. According to a multinational study by the
World Health Organization (WHO), cardiovascular dis-
ease is the leading cause of death among diabetic pa-
tients, accounting for 44% and 52% of deaths in patients
with types 1 and 2 diabetes mellitus, respectively [1]. In
long-term epidemiologic studies, the risk of coronary
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heart disease, stroke, or peripheral arterial disease was
2–3-times higher in diabetic patients than in patients
without diabetes [2–5].
Poor glycaemic control not only predicts an in-
creased risk of microvascular events, but is also an im-
portant risk factor for macrovascular complications,
such as cardiac or cerebrovascular events, in diabetic
patients [6, 7]. Large and functionally active platelets
are also known to contribute to thrombosis and athero-
sclerosis. The mean platelet volume (MPV) has been
shown to increase after myocardial infarction [8] and in
patients with diabetes [9]. In addition, the inflamma-
tion marker, C-reactive protein, and insulin resistance
are emerging as independent risk factors of cardiovas-
cular disease in several studies [10, 11].
Hyperbaric oxygen therapy (HBOT) is a well-known
treatment for diabetic foot ulcerations [12, 13]. The ben-
eficial effects of HBOT have been proposed for a vari-
ety of conditions. Recently, HBOT was observed to re-
duce the progression and accelerate the regression of
atherosclerosis in animal models [14, 15].
The aim of this study was to investigate the effect of
HBOT on glycaemic control, atherosclerosis, inflamma-
tory markers, and other clinical and laboratory param-
eters in patients undergoing systemic HBOT for dia-
betic foot ulcerations.
Material and methods
Twenty-eight diabetic patients (11 women and 17 men)
scheduled to undergo HBOT due to diabetic foot ulcer-
ations were included in this study. The inclusion crite-
ria were as follows: 1) diagnosis of type 2 diabetes for at
least 5 years, 2) Wagner scale 2–4 diabetic foot ulcer-
ation, 3) no contraindication against receiving HBOT,
and 4) prior written consent. HBOT was applied as
1 session per day, 5 times a week, over a 6 week period,
totalling 30 sessions. All patients were treated only with
insulin. None of the patients had received antihyper-
tensive or antilipidaemic therapy during the study pe-
riod. Each session consisted of 105 minutes of 100% ox-
ygen at 2.4x absolute atmosphere (ATA) pressure. Stan-
dard wound care was applied in addition to HBOT. The
study plan was reviewed and approved by our institu-
tional review committee, and informed consent was
obtained from all patients
The demographic properties and medical history of
all patients were recorded on the first visit, including
gender, weight, height, body mass index (BMI), dura-
tion of diabetes, and current diabetes treatment regi-
men. Fasting blood glucose (FBG), MPV, and high sen-
sitivity C-reactive protein (hs-CRP) levels were mea-
sured after session numbers 10, 20, and 30 of HBOT.
Haemoglobin A1c (HbA1c), homeostasis model measure-
ment-insulin resistance (HOMA-IR), uric acid, complete
blood count, (white blood cells [WBC], platelets, hae-
moglobin, and hematocrit), and lipid profile (high den-
sity lipoprotein [HDL], low density lipoprotein [LDL],
and triglycerides) were measured.
Statistical methods
SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA)
was used for statistical analysis. Numerical variables
were reported using descriptive statistics (mean ± stan-
dard deviation); categorical variables were reported as
percentages. Normal distribution was verified. Fasting
blood glucose, MPV, and hs-CRP variables were ana-
lyzed using variance analysis for multiple measure-
ments, and the LSD test was used for comparisons. The
paired samples test was used for comparisons of de-
pendent groups. The Student-t test was used for gen-
der comparisons. The Pearson correlation test was used
for correlation analysis. The statistical significance level
was set at p < 0.05.
Results
Twenty-eight patients between the ages of 40 and
54 years with diabetic foot (11 women and 17 men) were
included in this study. All patients were receiving insu-
lin treatment for type 2 diabetes. The mean duration of
diabetes history was 9.9 ± 2.2 years. The mean BMI was
26.8 ± 2.0 kg/m2. There was no significant difference
between the genders regarding the duration of diabetes
or BMI. According to the Wagner classification, 53.6% and
46.4% of the foot ulceration cases were grade 3 and 4,
respectively.
Glycaemic control was assessed by FBG and HbA1c.
HOMA-IR was calculated to determine the degree of
insulin resistance. Inflammation process was assessed
by hs-CRP and WBC counts. The lipid profile, uric acid
levels, platelet count, and MPV were measured as ath-
erosclerotic risk markers.
At baseline, the mean FBG was 152 ± 37 mg/dL and
the HbA1c was 9.1 ± 1.3%. The mean insulin resistance
was 7.9 ± 1.2. The complete blood count revealed mean
values of 13.8 ± 1.3 g/dL for haemoglobin, 35.3 ± 1.1 %
for hematocrit, 11.2 ± 3.0 x 103/µL for WBC, and 371 ±
± 91 × 103/µL for platelets. The mean MPV value was
13 ± 1.6 fL. The lipid profile was as follows: HDL, 35 ±
± 2 mg/dL; LDL, 122 ± 17 mg/dL; and triglycerides,
146 ± 33 mg/dL. The mean hs-CRP was 4.4 ± 1.3 mg/dL.
Between baseline and the completion of 30 sessions
of HBOT, a statistically significant improvement was
observed for the mean values of all assessed parame-
ters (Table I). For a more detailed follow-up of the ben-
eficial effects of HBOT, FBG, hs-CRP, and MPV, data
were collected at baseline and after sessions 10, 20, and
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30 of HBOT as representative markers of glycaemic con-
trol, inflammation, and atherosclerosis, respectively (Fig. 1).
Between baseline and the completion of HBOT, the FBG
decreased by 24.7% (± 13.7%) in 27 out of 28 patients.
The observed decrease was significant between each
pair of measurements (baseline-to-session 10, p < 0.001;
sessions 10-to-20, p = 0.026; and sessions 20-to-30, p =
= 0.005). Similarly, the hs-CRP and MPV values de-
creased significantly at each measurement (p < 0.001
for both [pairwise comparisons]). At baseline, the MPV
was above the normal range (7.3–10.1) for all patients,
while upon completion of treatment, the MPV dropped
to the normal range in 26 out of 28 patients.
Discussion
In this study we have shown that glycaemic control,
atherosclerosis, and inflammation markers were signif-
icantly improved in patients undergoing HBOT for di-
abetic foot ulcerations.
Table I. Baseline and post-hyperbaric oxygen treatment comparisons of glycaemic control, inflammation markers and
atherosclerosis risk factors
Tabela I. Porównanie kontroli glikemii, wskaźników zapalenia i czynników ryzyka miażdżycy przed i po leczeniu tlenem
w komorze hiperbarycznej
Baseline After HBO P value
(mean ± SD) (mean ± SD)
Glycaemic control and insulin resistance
FBG [mg/dL] 152 ± 37 113 ± 14 < 0.001
HbA1c (%) 9.1 ± 1.3 8.0 ± 1.1 < 0.001
HOMA-IR 7.9 ± 1.2 6.3 ± 1.0 < 0.001
Inflammation and atherosclerosis
hs-CRP [mg/dL] 4.4 ± 1.3 1.6 ± 0.7 < 0.001
WBC [× 103/mL] 11.2 ± 3.0 7.7 ± 2.1 < 0.001
MPV [fL] 13.0 ± 1.6 8.3 ± 1.2 < 0.001
Platelets [× 103/mL] 371 ± 91 275 ± 71 < 0.001
HDL [mg/dL] 35 ± 2 38 ± 8 < 0.001
LDL [mg/dL] 122 ± 17 104 ± 20 < 0.001
Uric acid [mg/dL] 9.6 ± 1.3 7.2 ± 1.1 < 0.001
HBO — hyperbaric oxygen; FBG — fasting blood glucose; HbA1c — haemoglobin A1c; HOMA-IR — homeostasis model measurement- insulin resistance;
hs-CRP — high sensitivity C-reactive protein; WBC — white blood cells; MPV — mean platelet volume; HDL — high density lipoprotein; LDL — low
density lipoprotein
Figure 1. Gradual decrease in mean values of glycaemic control (A), atherosclerosis (B), and inflammation (C) markers after sessions
10, 20, and 30 of hyperbaric oxygen treatment. P < 0.001 between all data points. FBG — fasting blood glucose; MPV — mean platelet
volume; hs-CRP — high sensitivity C-reactive protein
Rycian 1. Stopniowe zmniejszenie wartości wskaźników kontroli glikemii (A), miażdżycy (B) i zapalenia (C) po 10, 20 i 30 sesji
tlenoterapii w komorze hiperbarycznej. Wartość p < 0,001 dla wszystkich porównań. FBG — glikemia na czczo; MPV — średnia
objętość płytek krwi; hs-CRP — wysokoczułe białko C-reaktywne
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This is the first report in the English literature re-
garding the effects of HBOT on atherosclerosis in hu-
mans. A few reports in other languages involving dia-
betic patients with ischaemic extremities due to athero-
sclerosis were cited in a review by Al-Waili et al. [16].
The findings reported in these studies appear to be in
correlation with the findings reported in this study [17–
–19]. In terms of the effects of HBOT on glycaemic con-
trol, the decrease in blood glucose levels that we ob-
served in this study (24.7%) was consistent with the re-
duction in blood glucose levels (23%) reported in a study
investigating the effect of HBOT on blood pressure,
heart rate, and blood glucose [20].
Hyperbaric oxygen therapy involves the administra-
tion of 100% oxygen under high pressure conditions.
HBOT is used as an adjuvant therapy for a variety of con-
ditions, including chronic wounds, infections, oedema,
stroke, tissue transplantation, anaemia, and cancer man-
agement [16, 21]. HBOT is known to improve antibacteri-
al defences, increase blood flow, reduce oedema, main-
tain tissue oxygenation, stimulate fibroblast and collagen
production, and prevent lipid peroxidation [22]. The ex-
act mechanism by which HBOT leads to regression of ath-
erosclerosis and improves glycaemic control is unclear.
In animal models HBOT has been shown to attenu-
ate atherosclerosis in cholesterol-fed New Zealand
white rabbits and apoE knockout mice and to have
a powerful effect on the redox state of relevant tissues
[14, 15]. In addition, HBOT was found to attenuate
proinflammatory and immune responses to oxidized
LDL in apoE knockout mice [23].
A recent hypothesis postulated that HBO might ex-
ert its beneficial effects in diabetic patients by restora-
tion of vascular reactivity through modulating produc-
tion of vasoconstrictors and vasodilators and increas-
ing vessel sensitivity to these factors [24]. In support of
this hypothesis, HBO was found to alter the expression
of cyclooxygenase 2 (COX-2) and endothelial nitric ox-
ide synthase (eNOS) in experimental systems [25, 26],
and local nitric oxide (NO) levels were shown to increase
in diabetic foot patients responsive to HBO treatment
[27]. Since all the risk factors for atherosclerosis in dia-
betics are highly interrelated, the potential effect of HBO
on endothelial function per se could be sufficient to
explain the significant decrease that we have observed
in atherosclerotic, glycaemic, and inflammation mark-
ers. Indeed, endothelial dysfunction is closely associat-
ed with the development of diabetic retinopathy, neph-
ropathy, and atherosclerosis in both insulin-dependent
and non-insulin dependent diabetes [28]. In addition,
MPV, which recently emerged as a risk factor for ath-
erosclerosis, is associated with glycaemic control in dia-
betic patients [29]. Moreover, endothelial dysfunction
is intimately related to insulin resistance so that im-
proved tissue sensitivity to insulin improves vascular
endothelial function and vice versa [30].
Conclusions
The major limitation of this study was the absence of
a randomized control group with diabetic foot whose
ailments could be treated using standard wound care
instead of HBO treatment. Also, we did not follow up
the patients for extended periods to determine the du-
rability of the beneficial effects of HBO treatment. How-
ever, based on this preliminary data, we believe that
a larger randomized controlled clinical trial is required
to study the effects of HBO treatment on glycaemic con-
trol and atherosclerosis.
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